Viewing Study NCT02185560

Home Icon Home Search Icon Search Certify Doc Icon Certify Doc Certify Doc Icon Genes Certify Doc Icon Clinical Trials Certify Doc Icon CompTox Processes Icon DrugMatrix Open Targets Icon Open Targets Processes Icon Products Support Icon Support Bugs Icon Bugs
Main Search Make This Study a Gene Therapy Make This Study a Not Gene Therapy Report Bug
Ignite Creation Date: 2025-12-25 @ 2:13 AM
Ignite Modification Date: 2026-03-06 @ 2:31 PM
Study NCT ID: NCT02185560
Status: ACTIVE_NOT_RECRUITING
Last Update Posted: 2025-07-23
First Post: 2014-07-04
Is NOT Gene Therapy: True
Has Adverse Events: False
Brief Title: Prospective, Non-interventional, Post-authorization Safety Study That Includes All Patients Diagnosed as Unresectable Differentiated Thyroid Carcinoma and Treated With Sorafenib
Sponsor: Bayer
Organization:
Overview Dates Organization Conditions Design Enrollment Locations Outcomes Modules Raw JSON

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Thyroid Carcinoma View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Sorafenib View
None Differentiated Thyroid Carcinoma, View
None Japan View
None Post Marketing Surveillance View
None Drug Use Investigation View